Ticagrelor
Indication
Prevention of atherothrombotic events after myocardial infarction in adults. (NICE TA420)
NICE TA420 - Ticagrelor for preventing atherothrombotic events after myocardial infarction
Amber level 0
Brand:
Brilique
Nice TA:
420
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Cardiovascular system
Background
Ticagrelor, in combination with aspirin, is recommended within its marketing authorisation as an option for preventing atherothrombotic events in adults who had a myocardial infarction and who are at high risk of a further event. Treatment should be stopped when clinically indicated or at a maximum of 3 years.
Recommendation
LSCMMG Recommendation:
Amber level 0
Reason for decision:
Suitable for GP prescribing following recommendation/initiation by specialist
Supporting documents: